| Revista: | The brazilian journal of infectious diseases |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000291012 |
| ISSN: | 1413-8670 |
| Autores: | Tatsch, Fernando Franciosi1 Sette-Junior, Hoel2 Vianna, Denizar3 |
| Instituciones: | 1Roche Brazil, Rio de Janeiro. Brasil 2Universidade de Sao Paulo, Faculdade de Medicina, Sao Paulo. Brasil 3Universidade do Estado do Rio de Janeiro, Rio de Janeiro. Brasil |
| Año: | 2006 |
| Periodo: | Feb |
| Volumen: | 10 |
| Número: | 1 |
| Paginación: | 51-54 |
| País: | Brasil |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Analítico, descriptivo |
| Resumen en inglés | Life expectancy has increased over the last century as it had never been before. This is the result of a combination of many favorable variables such as level of education, improved socio-economic environment and development of medicine. However, new improvements demand heavy investment. Thus, the incorporation of medical technology became a health and economic issue. The pharmacoeconomic knowledge field is being developed to help in the analysis of medical costs and patient needs. The applies to hepatitic C, a common and chronic worldwide disease. In this article, the authors describe the rational behind this type of health economic analysis and review a hepatitis C model. Overall, in a non-Brazilian scenario, it was demonstrated that peginterferon alfa-2a (40KD) is cost effective in the treatment of HCV disease |
| Disciplinas: | Química, Economía, Medicina |
| Palabras clave: | Química farmacéutica, Economía de servicios, Gastroenterología, Farmacoeconomía, Hepatitis C, Peginterferon alfa-2a |
| Keyword: | Chemistry, Economics, Medicine, Medicinal chemistry, Service sector, Gastroenterology, Pharmacoeconomy, Hepatitis C, Peginterferon alfa-2a |
| Texto completo: | Texto completo (Ver HTML) |
